Jeisys Medical Inc. et al. v. Serendia, LLC

IPR2024-00384

EndyMed Medical Ltd. and EndyMed Medical Inc. jointly moved to terminate IPR2024-00384 after reaching a settlement with patent owner Serendia, LLC. The Board was asked to end the proceeding before any oral hearing or final decision.

Jurisdiction
US PTAB
Case Number
IPR2024-00384
Decision Date
1 August 2024
Filing Date
1 August 2024

Detailed Summary

In IPR2024-00384 concerning U.S. Patent No. 9,320,536, the petitioners EndyMed Medical Ltd. and EndyMed Medical Inc. and the patent owner Serendia, LLC have entered into a settlement that resolves all disputes over the patent. Pursuant to 35 U.S.C. §317 and related regulations, the parties filed a joint motion requesting the PTAB to terminate the inter partes review in its entirety. The motion notes that no oral hearing has been held and no final written decision issued, and cites precedent where the Board routinely grants such termination requests. The Board is thus asked to dismiss the proceeding.

Practitioner Note

This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Jeisys Medical Inc. et al. vs Serendia, LLC is valuable context for structuring arguments or assessing risk in similar proceedings.

Arctic Invent — IP Strategy

Dealing with a patent challenge?

Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.

Talk to our patent team →

Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.

Strategy Consult

Facing a similar patent matter?

Arctic's litigation team uses precedent data like this to build winning arguments.

Get a Strategy Call